SUNNYVALE, Calif., April 11, 2007 /PRNewswire-FirstCall/ -- Pharmacyclics, Inc. announced today multiple presentations regarding its novel histone deacetylase (HDAC) inhibitor and Bruton's tyrosine kinase inhibitor compounds. The presentations will take place at the American Association for Cancer Research (AACR) 2007 Annual Meeting being held April 14-18, 2007, at the Los Angeles Convention Center, in Los Angeles, CA.
The presentations are as follows: Sunday, April 15, 2007 Session: HDAC Inhibitors 1 Poster Presentation: Mechanisms of sensitivity in primary hematopoietic tumors and tumor lines to a novel HDAC inhibitor PCI-24781 Abstract #678: 8:00 a.m. -12:00 p.m. Presenter: Sriram Balasubramanian, Ph.D., Pharmacyclics, Inc. Session: HDAC Inhibitors 1 Poster Presentation: Radiosensitization by the HDAC inhibitor PCI-24781 in SiHa and WiDr human tumor cell lines Abstract #695: 8:00 a.m. -12:00 p.m. Presenter: Peggy L. Olive, Ph.D., British Columbia Cancer Research Center Monday, April 16, 2007 Session: Targeted Agents and Other Novel Therapies Poster Presentation: Identification of cross-validated functional biomarkers for a novel HDAC inhibitor PCI-24781, and their utility for selection of clinical indications Abstract #1830: 8:00 a.m. -12:00 p.m. Presenter: Sriram Balasubramanian, Ph.D., Pharmacyclics, Inc. Session: DNA Repair and Chemotherapeutic Agent Resistance Poster Presentation: Novel histone deacetylase (HDAC) inhibitor PCI-24781 disrupts RAD51 foci and inhibits homologous recombination Abstract #1966: 8:00 a.m. -12:00 p.m. Presenter: Shanthi Adimoolam, Ph.D., Pharmacyclics, Inc. Wednesday, April 18, 2007 Session: Kinases 1 Poster Presentation: PCI-31523: An irreversible inhibitor of Bruton's tyrosine kinase (Btk) that disrupts B cell receptor (BCR) signaling, is cytotoxic to B cell lympho mas, and is active in an animal arthritis model Abstract #5398: 8:00 a.m. -12:00 p.m. Presenter: Lee Honigberg, Ph.D., Pharmacyclics, Inc. Session: Miscellaneous Anticancer Agents Poster Presentation: Synthesis and anticancer properties of water-soluble zinc ionophores Abstract #5606: 8:00 a.m. -12:00 p.m. Presenter: Darren Magda, Ph.D., Pharmacyclics, Inc.
Pharmacyclics is a pharmaceutical company developing innovative products to treat cancer and other serious diseases. The company is leveraging its small-molecule drug development expertise to build a pipeline in oncology and other diseases based on a wide range of targets, pathways and mechanisms. Its lead product, Xcytrin(R) (motexafin gadolinium) Injection, has completed Phase 3 clinical trials and several ongoing Phase 1 and Phase 2 clinical trials are evaluating Xcytrin as a single agent or in combination with chemotherapy and/or radiation in multiple cancer types. More information about the company, its technology, and products can be found at www.pharmacyclics.com . Pharmacyclics(R), Xcytrin(R) and the "pentadentate" logo(R) are registered trademarks of Pharmacyclics, Inc.
NOTE: Other than statements of historical fact, the statements made in this press release about plans for our NDA filing, enrollment and future plans for our clinical trials, progress of and reports of results from preclinical and clinical studies, clinical development plans and product development activities are forward-looking statements, as defined in the Private Securities Litigation Reform Act of 1995. The words "believe," "will," "may," "continue," "plan," "expect," "intend," "anticipate," variations of such words, and similar expressions also identify forward-looking statements, but their absence does not mean that the statement is not forward-looking. The forwar d-looking statements are not guarantees of future performance and are subject to risks and uncertainties that may cause actual results to differ materially from those in the forward-looking statements. Factors that could affect actual results include risks associated with the possibility that the FDA declines to schedule an advisory panel meeting to review our NDA; the FDA refuses to approve our NDA; because our Phase 3 clinical trial known as the SMART (Study of Neurologic Progression with Motexafin Gadolinium And Radiation Therapy) trial failed to meet its primary endpoint, the FDA may require additional data, analysis or studies before the NDA is approved by the FDA; the outcome of any discussions with the FDA; the initiation, timing, design, enrollment and cost of clinical trials; unexpected delays in clinical trials and preparation of materials for submission to the FDA as part of our NDA filing; the fact that data from preclinical studies and Phase 1 or Phase 2 clinical trials may not necessarily be indicative of future clinical trial results; our ability to obtain future financing and fund the preparation of our NDA filing and the product development of our pipeline; our ability to establish successful partnerships and collaborations with third parties; the regulatory approval process in the United States and other countries; and our future capital requirements. For further information about these risks and other factors that may affect the actual results achieved by Pharmacyclics, please see the company's reports as filed with the U.S. Securities and Exchange Commission from time to time, including but not limited to its annual report on Form 10-K for the period ended June 30, 2006 and its subsequently filed quarterly reports on Form 10-Q. Forward-looking statements contained in this announcement are made as of this date, and we undertake no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise.
CONTACT: Leiv Lea of Pharmacyclics, Inc., +1-408-774-0330; or CarolynBumgardner Wang of WeissComm Partners, +1-415-946-1065, for Pharmacyclics,Inc.
Web site: http://www.pharmacyclics.com/
Ticker Symbol: (NASDAQ-NMS:PCYC)
Terms and conditions of use apply
Copyright © 2007 PR Newswire Association LLC. All rights reserved.
A United Business Media Company